Led by a world class management team with a successful entrepreneurial track record and supported by a syndicate of top investors, Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers.

Our multispecific antibodies are designed to enhance and direct the power of key effector cells of the innate and adaptive immune system, providing a safer, more tailored alternative to CD3 based engagers.